0001104659-26-056778
SEC filingRevenue accelerated 45% YoY to $71.4M from Amtagvi® and Proleukin® sales, driving gross profit to $28.9M and narrowing net loss 32% to $79.0M, reflecting commercial scale amid ongoing R&D and expansion investments.
Revenue increased 44.8% year-over-year to $71.4 million in Q1 FY2026 from $49.3 million, primarily due to higher sales of Amtagvi® and Proleukin® products. This growth reflects momentum in our commercial launch, enabling the company to generate meaningful top-line progress while scaling cell therapy delivery.
Gross profit swung to $28.9 million, a 40.5% margin on revenue, compared to a $417 thousand loss in the prior year. This emergence of positive gross profit validates manufacturing efficiencies at scale, as higher volumes of Amtagvi® infusions leverage fixed production costs in our controlled iCTC facility, which supports full oversight of quality, logistics, and process improvements like automation.
Operating loss narrowed 33.1% to $81.0 million from $121.2 million, with operating margin at -113.5%. The improvement stems from revenue leverage, as product sales growth outpaced expense categories despite investments in expansion. Net loss followed suit, decreasing 32.0% to $79.0 million from $116.2 million, with diluted EPS at -$0.19 versus -$0.36. Management attributes this primarily to the revenue increase from Amtagvi® and Proleukin®.